Читать книгу Recent Advances in the Pathogenesis and Treatment of Kidney Diseases - Группа авторов - Страница 25

Rituximab infusion was globally well tolerated. The risk of adverse effects attributed to rituximab varies. With rituximab treatment, the most commonly reported adverse effects are infusion reactions, such as rash and chills; these reactions can be managed by pre-medication or infusion rate adjustments [2]. Each of these reactions is thought to be associated with an underlying disease or to be a result of concomitant immunosuppressive therapy, rather than a direct result of rituximab administration. We have recently assessed the improvement in adverse effects of steroids and the safety of rituximab treatment in adults with steroid-dependent MCNS [18]. A total of 54 adult patients were treated with 4 single-dose 6-monthly infusions of rituximab and the adverse effects with steroids between the first rituximab infusion (baseline) and the end of the 24-month observation period compared. The steroid dose was significantly lower at 24 months than at the baseline. Eight patients with diabetes mellitus showed improved glycemic control at 24 months as compared to that at the baseline. There were no severe adverse effects of rituximab.